The FRESCO-2 study was a multi-regional clinical trial conducted in the U. , Europe, Japan and Australia that investigated fruquintinib plus best supportive care (BSC) vs placebo plus BSC in patients with metastatic CRC who had progressed on standard chemotherapy and relevant biologic agents and who had progressed on, or were intolerant to, TAS-102 andor regorafenib.
🌍 HUTCHMED DRC (HCM) - Form 6-K Filing
Filing Date: 2022-08-08
Accepted: 2022-08-08 06:24:56
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: